Free Trial
OTCMKTS:HYPMY

Hypera (HYPMY) Stock Price, News & Analysis

Hypera logo
$3.29 -0.10 (-2.81%)
As of 04/11/2025 12:45 PM Eastern

About Hypera Stock (OTCMKTS:HYPMY)

Key Stats

Today's Range
$3.29
$3.35
50-Day Range
$3.10
$3.68
52-Week Range
$2.64
$6.03
Volume
710 shs
Average Volume
8,226 shs
Market Capitalization
$2.08 billion
P/E Ratio
8.23
Dividend Yield
3.95%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Remove Ads
Receive HYPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

HYPMY Stock News Headlines

Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Hypera S.A. Reports 2024 Financial Performance
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera: Short-Term Pain For Long-Term Gain
Hypera S.A. Reports Strategic Shift Amid Revenue Decline
See More Headlines

HYPMY Stock Analysis - Frequently Asked Questions

Hypera's stock was trading at $3.06 at the start of the year. Since then, HYPMY stock has increased by 7.5% and is now trading at $3.29.
View the best growth stocks for 2025 here
.

Hypera S.A. (OTCMKTS:HYPMY) announced its quarterly earnings data on Thursday, March, 20th. The company reported $0.02 EPS for the quarter. The business earned $258.56 million during the quarter. Hypera had a trailing twelve-month return on equity of 13.18% and a net margin of 20.04%.

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/20/2025
Today
4/15/2025
Next Earnings (Estimated)
4/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:HYPMY
Fax
N/A
Employees
10,301
Year Founded
N/A

Profitability

Trailing P/E Ratio
8.23
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$330.61 million
Pretax Margin
18.33%

Debt

Sales & Book Value

Annual Sales
$1.59 billion
Cash Flow
$0.55 per share
Price / Cash Flow
6.02
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.08 billion
Optionable
Not Optionable
Beta
0.75
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:HYPMY) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners